The recently published phase 1 of bb2121 CAR-T cell therapy targeting BCMA for relapsed and/or refractory MM with at least 3 prior lines of therapies showed ORR of 85%, including 45% patients with complete responses [153]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.